Patents by Inventor Samarth Kumar
Samarth Kumar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115523Abstract: The present invention provides a ready to use stable aqueous dosage form of norepinephrine comprising an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, one or more sulfite antioxidants and an ion chelator. The present invention also provides an infusion container filled with an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, wherein the said solution is stable for a prolonged period of time and can be terminally sterilized by autoclaving.Type: ApplicationFiled: November 21, 2023Publication date: April 11, 2024Inventors: Samarth KUMAR, Maheshkumar Parasmal SONI, Praveen Kumar SRIVASTAVA, Prashant KANE, Subhas Balaram BHOWMICK
-
Publication number: 20240099965Abstract: The present disclosure relates to a ready-to-use or a ready to administer parenteral dosage form of oxytocin or a pharmaceutically acceptable salt thereof comprising a ready-to-infuse, stable aqueous solution of oxytocin or a pharmaceutically acceptable salt thereof. The solution can be administered to a patient in need thereof without manipulations in terms of its concentration and is stable for a prolonged period of time.Type: ApplicationFiled: February 3, 2022Publication date: March 28, 2024Inventors: Samarth KUMAR, Neeraj Kumar GARG, Ajay Jaysingh KHOPADE, Subhas Balaram BHOWMICK
-
Patent number: 11920148Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with ANGPTL3 whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of ANGPTL3 gene in a cell by genome editing.Type: GrantFiled: February 21, 2018Date of Patent: March 5, 2024Assignee: CRISPR THERAPEUTICS AGInventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan, Yvonne Sarah Aratyn
-
Publication number: 20240066150Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with SCN10A whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of SCN10A gene in a cell by genome editing.Type: ApplicationFiled: September 13, 2023Publication date: February 29, 2024Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
-
Patent number: 11865089Abstract: The present invention provides a ready to use stable aqueous dosage form of norepinephrine comprising an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, one or more sulfite antioxidants and an ion chelator. The present invention also provides an infusion container filled with an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, wherein the said solution is stable for a prolonged period of time and can be terminally sterilized by autoclaving.Type: GrantFiled: October 18, 2021Date of Patent: January 9, 2024Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Samarth Kumar, Maheshkumar Parasmal Soni, Praveen Kumar Srivastava, Prashant Kane, Subhas Balaram Bhowmick
-
Publication number: 20230364106Abstract: A parenteral dosage form of diltiazem, comprising a ready-to-infuse, stable aqueous solution comprising diltiazem or its pharmaceutically acceptable salt, a pharmaceutically acceptable stabilizer selected from cyclic oligosaccharides, and an infusion container fdled with the said aqueous solution.Type: ApplicationFiled: September 21, 2021Publication date: November 16, 2023Inventors: Samarth KUMAR, Milan Mohanbhai VASOYA, Devendra Pratap SINGH, Ajay Jaysingh KHOPADE, Subhas Balaram BHOWMICK
-
Patent number: 11793719Abstract: The present invention relates to a method for enabling hospitals or clinics to administer a dose of a drug to patients in need thereof while avoiding steps of manipulation, dilution, reconstitution, dispensing, sterilization, transfer, handling or compounding before intravenous administration. The present invention further relates to a perfusion system comprising different sets of perfusion containers, each container comprising a ready-to-infuse, stable, sterile, aqueous perfusion solution of a drug, wherein the set of perfusion containers alone or in combination provides for direct intravenous administration of a desired dose of the drug to a patient in need thereof, such that the delivered dose is equal to or within ±5% of the calculated dose.Type: GrantFiled: September 20, 2022Date of Patent: October 24, 2023Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Samarth Kumar, Prashant Kane, Subhas Balaram Bhowmick, Kirti Ganorkar, Nishit Patel, Ashish Anilrao Dubewar, Umeshkumar Mukeshbhai Patel
-
Publication number: 20230158226Abstract: A perfusion container for directly administering to patients a dose of an antineoplastic drug calculated according to a patient's parameter, wherein the first perfusion container comprises a solution of antineoplastic drug at a concentration and volume such that the amount of antineoplastic drug in the container is equal to the calculated dose for one patient but less than the calculated dose for a second patient, the calculated dose is provided to first patient within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container, further the first perfusion container is accompanied by a second top-up perfusion container comprising a solution of antineoplastic drug at a concentration and volume such that the calculated dose is provided within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container and the second top-up container to the second patient.Type: ApplicationFiled: November 21, 2022Publication date: May 25, 2023Inventors: Subhas Balaram BHOWMICK, Prashant KANE, Samarth KUMAR, Kirti GANORKAR
-
Publication number: 20230140586Abstract: A parenteral dosage form having an infusion container filled with an aqueous solution in volumes ranging from 40 ml to 500 ml comprising 1 mg/ml to 2 mg/ml of carboplatin, wherein the solution contains known impurity of 1, 1-cyclobutanedicarboxylic acid in an amount of not more than 1.0% by weight of carboplatin and the solution remains physically stable when stored at room temperature.Type: ApplicationFiled: August 30, 2019Publication date: May 4, 2023Inventors: Samarth KUMAR, Maheshkumar Parasmal SONI, Subhas Balaram BHOWMICK, Prashant KANE
-
Publication number: 20230087099Abstract: The present invention relates to a method for enabling hospitals or clinics to administer a dose of a drug to patients in need thereof while avoiding steps of manipulation, dilution, reconstitution, dispensing, sterilization, transfer, handling or compounding before intravenous administration. The present invention further relates to a perfusion system comprising different sets of perfusion containers, each container comprising a ready-to-infuse, stable, sterile, aqueous perfusion solution of a drug, wherein the set of perfusion containers alone or in combination provides for direct intravenous administration of a desired dose of the drug to a patient in need thereof, such that the delivered dose is equal to or within ±5% of the calculated dose.Type: ApplicationFiled: September 20, 2022Publication date: March 23, 2023Inventors: Samarth Kumar, Prashant KANE, Subhas Balaram BHOWMICK, Kirti GANORKAR, Nishit PATEL, Ashish Anilrao DUBEWAR, Umeshkumar Mukeshbhai PATEL
-
Patent number: 11554207Abstract: A perfusion container for directly administering to patients a dose of an antineoplastic drug calculated according to a patient's parameter, wherein the first perfusion container comprises a solution of antineoplastic drug at a concentration and volume such that the amount of antineoplastic drug in the container is equal to the calculated dose for one patient but less than the calculated dose for a second patient, the calculated dose is provided to first patient within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container, further the first perfusion container is accompanied by a second top-up perfusion container comprising a solution of antineoplastic drug at a concentration and volume such that the calculated dose is provided within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container and the second top-up container to the second patient.Type: GrantFiled: February 9, 2017Date of Patent: January 17, 2023Assignee: SUN PHARMACEUTICAL INDUSTRIES LTD.Inventors: Subhas Balaram Bhowmick, Prashant Kane, Samarth Kumar, Kirti Ganorkar
-
Publication number: 20220233403Abstract: The invention relates to an infusion container comprising a sterile, ready-to-use, stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof, suitable for direct intravenous infusion to a patient in need thereof. The invention also relates to a novel infusion container having plurality of ports that is suitable for delivering or receiving a sterile fluid, such as the said stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: January 3, 2022Publication date: July 28, 2022Inventors: Samarth Kumar, Maheshkumar Parasmal Soni, Nishit Patel, Prashant Kane, Subhas Balaram Bhowmick
-
Patent number: 11273100Abstract: The invention relates to an infusion container comprising a sterile, ready-to-use, stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof, suitable for direct intravenous infusion to a patient in need thereof. The invention also relates to a novel infusion container having plurality of ports that is suitable for delivering or receiving a sterile fluid, such as the said stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 20, 2020Date of Patent: March 15, 2022Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Samarth Kumar, Maheshkumar Parasmal Soni, Nishit Patel, Prashant Kane, Subhas Balaram Bhowmick
-
Publication number: 20220054434Abstract: The present invention provides a ready to use stable aqueous dosage form of norepinephrine comprising an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, one or more sulfite antioxidants and an ion chelator. The present invention also provides an infusion container filled with an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, wherein the said solution is stable for a prolonged period of time and can be terminally sterilized by autoclaving.Type: ApplicationFiled: October 18, 2021Publication date: February 24, 2022Inventors: Samarth Kumar, Maheshkumar Parasmal Soni, Praveen Kumar Srivastava, Prashant Kane, Subhas Balaram Bhowmick
-
Patent number: 11253642Abstract: A perfusion container for directly administering to patients a dose of an antineoplastic drug calculated according to a patient's parameter, wherein the first perfusion container comprises a solution of antineoplastic drug at a concentration and volume such that the amount of antineoplastic drug in the container is equal to the calculated dose for one patient but less than the calculated dose for a second patient, the calculated dose is provided to first patient within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container, further the first perfusion container is accompanied by a second top-up perfusion container comprising a solution of antineoplastic drug at a concentration and volume such that the calculated dose is provided within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container and the second top-up container to the second patient.Type: GrantFiled: December 18, 2020Date of Patent: February 22, 2022Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Subhas Balaram Bhowmick, Prashant Kane, Samarth Kumar, Kirti Ganorkar
-
Patent number: 11246801Abstract: The invention relates to an infusion container comprising a sterile, ready-to-use, stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof, suitable for direct intravenous infusion to a patient in need thereof. The invention also relates to a novel infusion container having plurality of ports that is suitable for delivering or receiving a sterile fluid, such as the said stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 4, 2020Date of Patent: February 15, 2022Assignee: Sun Pharmaceutical Industries LimitedInventors: Samarth Kumar, Maheshkumar Parasmal Soni, Nishit Patel, Prashant Kane, Subhas Balaram Bhowmick
-
Patent number: 11241379Abstract: The present invention relates to a parenteral dosage form comprising a) a ready-to-infuse, stable aqueous solution comprising diltiazem or its pharmaceutically acceptable salt, pH adjusting agent to provide a pH in the range of 3 to 5 and ethanol, and b) an infusion container filled with said aqueous solution.Type: GrantFiled: December 1, 2016Date of Patent: February 8, 2022Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Samarth Kumar, Milan Natvarbhai Thakkar, Kandarp Maheshkumar Dave
-
Publication number: 20220000776Abstract: The present invention provides a parenteral dosage form consisting essentially of a solution filled in a container, the solution comprising amiodarone or its pharmaceutically acceptable salt and a sulfo-alkyl ether beta-cyclodextrin in an aqueous vehicle, wherein the solution has a pH in the range of about 2.4 to 3.9 and further wherein the dosage form is sterilized by subjecting the filled container to autoclaving.Type: ApplicationFiled: September 15, 2021Publication date: January 6, 2022Inventors: Samarth Kumar, Soni Maheshkumar Parasmal, Milan Mohanbhai Vasoya, Prashant Kane, Subhas Balaram Bhowmick, Rajamannar Thennati
-
Publication number: 20210401669Abstract: The invention relates to an infusion container comprising a sterile, ready-to-use, stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof, suitable for direct intravenous infusion to a patient in need thereof. The invention also relates to a novel infusion container having plurality of ports that is suitable for delivering or receiving a sterile fluid, such as the said stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 4, 2020Publication date: December 30, 2021Inventors: Samarth KUMAR, Maheshkumar Parasmal SONI, Nishit PATEL, Prashant KANE, Subhas Balaram BHOWMICK
-
Patent number: 11197838Abstract: The present invention provides a ready to use stable aqueous dosage form of norepinephrine comprising an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, one or more sulfite antioxidants and an ion chelator. The present invention also provides an infusion container filled with an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, wherein the said solution is stable for a prolonged period of time and can be terminally sterilized by autoclaving.Type: GrantFiled: August 10, 2020Date of Patent: December 14, 2021Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Samarth Kumar, Maheshkumar Parasmal Soni, Praveen Kumar Srivastava, Prashant Kane, Subhas Balaram Bhowmick